16531-04-7

Usage

Uses

Used in Pharmaceutical Industry:
1',2'-Didehydro-7',10,11-trimethoxyemetan-6',9-diol is used as a pharmaceutical compound for its potential therapeutic effects. The expression is: 1',2'-Didehydro-7',10,11-trimethoxyemetan-6',9-diol is used as a pharmaceutical compound for its unique chemical structure and potential therapeutic applications.
Used in Chemical Research:
In the field of chemical research, 1',2'-Didehydro-7',10,11-trimethoxyemetan-6',9-diol serves as a valuable compound for studying the properties and reactions of isoquinoline alkaloids. The expression is: 1',2'-Didehydro-7',10,11-trimethoxyemetan-6',9-diol is used as a research compound for understanding the characteristics and reactions of isoquinoline alkaloids.
Used in Drug Development:
1',2'-Didehydro-7',10,11-trimethoxyemetan-6',9-diol is utilized as a starting material or intermediate in the synthesis of various drugs, particularly those targeting specific biological pathways. The expression is: 1',2'-Didehydro-7',10,11-trimethoxyemetan-6',9-diol is used as a starting material or intermediate in drug development for its potential role in synthesizing therapeutically relevant compounds.

Upstream product

• 61194-41-0 (+/-)-8-benzyloxy-3α-ethyl-1,3,4,6,7,11bα-hexahydro-9,10-dimethoxy-2H-benzoquinolizine-2β-acetic acid 
• 61194-41-0 (2R,3R,11bS)-(-)-8-benzyloxy-3-ethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2H-benzoquinolizine-2-acetic acid 
• 61194-42-1 (+/-)-8-benzyloxy-N-(3-benzyloxy-4-methoxyphenethyl)-3α-ethyl-1,3,4,6,7,11bα-hexahydro-9,10-dimethoxy-2H-benzoquinolizine-2β-acetamide 
• 56774-72-2 ethyl (+/-)-8-benzyloxy-3α-ethyl-1,3,4,6,7,11bα-hexahydro-9,10-dimethoxy-2H-benzoquinolizine-2β-acetate 
• 36455-21-7 3-benzyloxy-4-methoxyphenylethylamine 
• 61194-43-2 (+/-)-8-benzyloxy-2β-(6-benzyloxy-3,4-dihydro-7-methoxy-1-isoquinolyl)methyl-3α-ethyl-1,3,4,6,7,11bα-hexahydro-9,10-dimethoxy-2H-benzoquinolizine 
• 57130-35-5 (2R,3R,11bS)-(-)-8-(Benzyloxy)-3-ethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2H-benzoquinolizine-2-acetic Acid Ethyl Ester 
• 61194-42-1 (2R,3R,11bS)-(-)-8-benzyloxy-N-(3-benzyloxy-4-methoxyphenethyl)-3-ethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2H-benzoquinolizine-2-acetamide 

Relevant academic research and scientific papers

Quinolizidines. VIII. Structure and Synthesis of the Alangium Alkaloid Alangicine: Syntheses of (+/-)- and (+)-Alangicines

The first total synthesis of alangicine (3), an Alangium lamarckii alkaloid, has been achieved in the form of a racemic modification by means of an initial alkaline hydrolysis of the (+/-)-tricyclic ester 6 and succeeding steps proceeding through the intermediates (+/-)-7, (+/-)-10, and (+/-)-9.A parallel synthetic route starting with the (-)-tricyclic ester 6, derived from (+)-cincholoipon ethyl ester (8), produced the chiral target molecule (+)-3 via the intermediates (-)-7, (-)-10, and 9.The identity of the synthetic (+)-3 with alangicine unequivocally established the structure and absolute stereochemistry of this alkaloid.The (13)C nuclear magnetic resonance spectra of (+/-)-alangicine (3) and the ipecac and Alangium alkaloid psychotrine (18) confirmed their endocyclic double bond structures in the dihydroisoquinoline moiety.Catalytic reductions of 11, (+/-)-12, and 15 using hydrogen and Pd-C were investigated, and the results have shown that hydrogenolysis of the benzyloxy group proceeds much faster than saturation of the endocyclic C=N bond.Keywords - alangicine; psychotrine; structure; absolute configuration; stereoselective synthesis; (13)C NMR; CD; benzyl ether; hydrogenolysis